186
Views
14
CrossRef citations to date
0
Altmetric
Review

An update on intrasaccular flow disruption for the treatment of intracranial aneurysms

, , &
Pages 229-236 | Received 13 Nov 2018, Accepted 05 Feb 2019, Published online: 26 Feb 2019
 

ABSTRACT

Introduction: Intrasaccular flow disruption is an innovative technique for the endovascular treatment of intracranial aneurysms. Among flow disrupting devices, the Woven EndoBridge (WEB) is currently the only flow disrupter on the market and has seen an extensive scientific evaluation. It was shown that the device provides a safe and effective treatment particularly for wide-neck aneurysms of proximal bifurcations.

Areas covered: We describe the principal concept and the technical evolution of intrasaccular flow disruption and discuss all devices that have to date been presented, with a special focus on the WEB. Key results of the literature are summarized, and we review possible future indications for this innovative treatment concept.

Expert commentary: The tools for the endovascular management of intracranial aneurysms continue to evolve rapidly with intrasaccular flow disruption being the most recent innovation in the field. The WEB is currently the only device on the market. Compared to competing techniques, intrasaccular flow disruption offers several advantages and it is likely that given the technically straightforward nature of the procedure and the high-quality scientific evidence of its safety and efficacy, the device will see a progressive expansion of its indications and will replace standard coiling in an increasing number of cases.

Declaration of interest

Laurent Pierot has done consultancy work for Balt, MicroVention, Vesalio, Penumbra, and Cerenovus. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

One peer reviewer is a shareholder of Phenox GmbH. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.